(BUSINESS WIRE) Pfizer Inc today reviewed strategies to accelerate and refocus Pfizer’s pipeline and capture new opportunities for global growth at a meeting for investment analysts. “We have made real changes in how we operate our business – in our structure, culture and leadership – so that we have a much stronger foundation in place for pursuing the many opportunities before us,” said Chairman
Press Release Archive
March 4, 2008 - Pfizer Presents New Opportunities for Global Growth
(BUSINESS WIRE) Pfizer Inc today named William Ringo as the company’s new Senior Vice President of Strategy and Business Development with responsibility for guiding Pfizer’s overall strategic planning and business development activities, reporting to Chairman and Chief Executive Officer Jeff Kindler. He will join Pfizer’s Executive Leadership Team. Mr. Ringo is a senior corporate bio-pharmaceutical executive with
(BUSINESS WIRE) Pfizer Inc today announced that it has entered into an agreement to acquire Serenex, Inc., a privately-held biotechnology company with a Phase I clinical candidate and an extensive compound library that targets Heat Shock Protein 90 (Hsp90), an exciting target in the fight against cancer. As per the agreement, Pfizer will acquire the rights to SNX-5422, an oral Hsp90 inhibitor currently in Phase I trials for the
(BUSINESS WIRE)-- Pfizer Inc said today that it will seek to appeal a ruling of the Court of Appeal of The Hague in the Netherlands that Pfizer’s atorvastatin enantiomer patent is invalid. The patent (EP 409,281) had been challenged by generics manufacturer Ranbaxy and expires in July 2010. The decision has no commercial impact because Pfizer’s basic patent covering Lipitor (EP 247,633) remains in force and expires
February 25, 2008 - Pfizer Voluntarily Withdraws Lipitor Advertising Featuring Dr. Robert Jarvik
(BUSINESS WIRE)--Pfizer said today that it is voluntarily withdrawing Lipitor advertising and promotion featuring Dr. Robert Jarvik and committing to ensuring greater clarity in the roles and responsibilities of its spokespeople in its consumer advertising and promotion. Commenting on the withdrawal of the Jarvik advertising and promotion, Pfizer’s President of Worldwide Pharmaceutical Operations Ian Read said
(BUSINESS WIRE)--Pfizer Inc said today that the Court of Appeal of The Hague in the Netherlands has ruled that the basic patent covering atorvastatin - the active ingredient in Lipitor - would be infringed by a competitor product from generics manufacturer Ranbaxy. The decision prevents Ranbaxy from launching its drug before Lipitor’s basic patent (EP 247,633) expires in November 2011. “Today’s decision is
February 19, 2008 - Pfizer to Acquire Encysive Pharmaceuticals
(BUSINESS WIRE)--NEW YORK
February 12, 2008 - Pan-African Conference Focuses on Keeping the Medicine Supply in Africa Safe
(BUSINESS WIRE)--An international conference to discuss the issue of counterfeit medicines in Africa started this week in Johannesburg. The aim of the conference, which is sponsored by Pfizer, is for representatives from sub-Saharan countries to discuss the threats that counterfeit medicines and unregistered generics pose for the safety of patients in this region and to develop joint plans of action to address this issue
February 12, 2008 - Pan-African Conference Focuses on Keeping the Medicine Supply in Africa Safe
(BUSINESS WIRE)--An international conference to discuss the issue of counterfeit medicines in Africa started this week in Johannesburg. The aim of the conference, which is sponsored by Pfizer, is for representatives from sub-Saharan countries to discuss the threats that counterfeit medicines and unregistered generics pose for the safety of patients in this region and to develop joint plans of action to address this issue
(BUSINESS WIRE)--At this week’s major HIV/AIDS research meeting, Pfizer presented new data on two investigational second generation HIV compounds – a CCR5 antagonist and a non-nucleoside reverse transcriptase inhibitor (NNRTI). Pfizer also presented additional data on SelzentryTM (maraviroc) tablets, its first-in-class medicine approved last year for use in treatment-experienced HIV patients infected with a certain type of
(BUSINESS WIRE)--Pfizer Japan Inc (headquarter in Shibuya-ku, Tokyo; headed by President & Chief Executive Officer, Hiromitsu Iwasaki; and capitalized at Yen 64.8 billion) announced that on January 25, the company received manufacturing and marketing authorization for Champix® Tablet 0.5 mg/1mg (varenicline tartrate), a smoking cessation aid for smokers dependent on nicotine. Champix is Japan’s first oral smoking
Pfizer Inc (NYSE: PFE): ($ in millions, except per share amounts) Fourth Quarter Full Year 2007 2006 Change
January 21, 2008 - Make a New Year's Resolution to Lose Weight - For Your Dog
(BUSINESS WIRE)--As millions of Americans vow to get healthier and stave off illness by making a New Year’s resolution to lose weight, it’s time for dog owners to make a similar pledge for their furry friends. Recent studies indicate that 25 to 40 percent of U.S. dogs – approximately 17 million – are overweight or obese and potentially facing serious health problems. What’s more troubling is that
(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a meeting with investment analysts being held on Wednesday, March 5, at 8:30a.m. Eastern Standard Time. The purpose of the meeting is to discuss the Company’s strategic direction. Jeffrey B. Kindler, Pfizer chairman and chief executive officer, will host the meeting. To view and listen to the webcast, visit our web site
(BUSINESS WIRE)--Cigarette smoking is associated with significant morbidity and mortality. Smoking is the leading preventable cause of disease and premature death in the United States, with more than 438,000 U.S. deaths annually attributable to smoking. Patients who smoke cigarettes should be counseled to quit. CHANTIX® was approved in May of 2006 in the U.S. as an aid to smoking cessation. Based upon post-marketing reports
(BUSINESS WIRE)-- Pfizer Inc today announced the eighth class of Global Health Fellows, a group of 28 Pfizer colleagues from North America, Europe and Asia, who will partner with non-governmental organizations (NGOs) and multilateral organizations (MLOs) in developing countries to help build health care infrastructure while on dedicated 4-6 month assignments. The Pfizer Global Health Fellows program is one of the first public-
(BUSINESS WIRE)--The early addition of Lipitor® (atorvastatin calcium) Tablets to effective blood pressure lowering treatment maintained a significant 36 percent reduction in the relative risk of fatal or non-fatal heart attacks over five years, according to a new analysis. This was a post-hoc analysis (designed and completed following the closure of the trial) of the lipid-lowering arm of the Anglo-Scandinavian Cardiac
January 15, 2008 - Pfizer and Scil Finalize Agreement for Novel Cartilage Growth Factor
(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) and Scil Technology GmbH (Scil) have signed a licensing agreement for worldwide collaboration on Scil’s cartilage specific growth factor CD-RAP. Under this agreement, Pfizer will obtain a worldwide exclusive license to develop and commercialize CD-RAP. In addition to receiving royalties on the sale of any products that may be commercialised under this agreement, Scil is eligible for
(BUSINESS WIRE)--European vets are about to be given the same powerful medical tool which has helped U.S. vets manage obese dogs who don’t respond to exercise and diet. Since Pfizer Animal Health’s SLENTROLTM was introduced eight months ago in the U.S., thousands of obese dogs have benefited from healthier weights and more active lives. Now, European vets will be able to talk to dog owners about Slentrol as
Pages
Press release archive foot note
Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.
Stay on top of Pfizer breaking news: Get News Alerts by RSS. 
Stock Quote Disclaimer
20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.
 |
If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page. |
Current Stock Price
| . |
. . |
| %Change | . | 52 Wk. High | . |
| Day High | . | 52 Wk. Low | . |
| Day Low | . | Mkt. Cap(Bil) | . |
| Open | . | ||
| Prev Close | . | Symbol | . |
| Vol. | . | Exchange | . |
Online Pfizer Press Kit
Our press kit provides information that might help you write stories or simply find out more about Pfizer.